Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe 2.5mg dose of Mounjaro is designed as a four-week starter, not a long-term treatment dose. Most people move on after one pen. But how long you stay on 2.5mg Mounjaro depends on how your body settles in during those first weeks — and that decision belongs to your prescriber, not a timer. Mounjaro (tirzepatide) is a prescription-only medicine, so any change to your dose is made clinically, based on your individual response.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide activates two gut-hormone receptors simultaneously (GIP and GLP-1) which is what makes it distinct from other weight-loss medicines. That dual action is also why the body can take a little time to adjust. Starting at a lower dose means the nausea, indigestion and fatigue that some people notice are far less likely to derail treatment in the first few weeks.
So 2.5mg is not a therapeutic dose in the way that 10mg or 15mg is. The first pen's job is adjustment. You are not expected to see significant weight loss at 2.5mg, and if you notice very little happening, that is by design. The NHS tirzepatide medicines page describes this clearly: the dose is titrated upwards as tolerability is established.
That framing matters if you are feeling impatient four weeks in. The starter dose is doing something — it is just doing it quietly, getting your gut used to a mechanism it has never encountered before. Most people find the therapeutic benefit becomes clearer once they have moved through a couple of dose steps.
The licensed schedule, as described in the Mounjaro SmPC, is four weeks at each dose level. For the vast majority of people, one four-week pen at 2.5mg is the plan, followed by a move to 5mg. If you ordered on a Monday in the middle of the month, your next order and clinical review would typically fall around the same time the following month, timing can be useful to plan around a payday or a holiday, since you will want your pen in the fridge before you travel.
That said, your prescriber may advise staying on 2.5mg for an additional four weeks if side effects have been particularly troublesome and have not yet settled. This is not unusual. The guidance from NICE's appraisal of tirzepatide (TA1026) supports flexibility in titration to balance tolerability against progress. What the guidance does not support is staying at 2.5mg indefinitely if it is well tolerated, because the medicine's weight-management evidence base is built on reaching higher maintenance doses.
If you are wondering whether to push through to 5mg or sit tight, our page on whether to stay on 2.5mg Mounjaro covers the specific factors worth considering before your next review.
Remaining on 2.5mg for eight or twelve weeks rather than four is not dangerous. The medicine is the same compound; the dose is simply lower than where it needs to be for most people's treatment goals. The practical consequence is that weight loss is likely to be minimal during that extended period, which can feel disheartening when you are trying to judge whether treatment is working.
There is also a secondary consideration. If treatment is extended at 2.5mg without a clinical reason, it may affect the timeline for reaching a dose where the published evidence (including the SURMOUNT-1 trial, in which average weight reduction reached around 20–21% at the highest doses) begins to apply to your situation. The dose you are on now is not the dose those results were measured at.
For people thinking through the 5mg transition specifically, our guide on how long to stay on 5mg Mounjaro picks up the question at that next stage. And if you are preparing for your very first injection, practical tips for your first Mounjaro dose covers the things it helps to know before you start.
Your prescriber. Not you, not a generic schedule printed on a box. This is not a formality, it is a genuine clinical assessment of how your body responded during the starter phase, what side effects you experienced, and whether there is any reason to delay titration. At nume, every repeat order goes through this re-review before anything is dispatched. A real clinician reads your responses; nothing is automated.
That matters particularly because some people arrive at the 5mg decision having had a rougher first four weeks than they expected. Others feel fine and want to move quickly. Both are valid data points for a prescriber to work with. If you have questions about how long you stay on 2.5mg Mounjaro before that transition, a short message through our support team can get your question in front of the right person before your next order is due.
You can read more about how our clinical team approaches these decisions on our prescriber profile page, or explore the broader picture of Mounjaro as a weight-management medicine if you are still building your understanding of tirzepatide. For people weighing up whether the move to 5mg is right for them, our page on whether to stay on 5mg Mounjaro sets out the key considerations in one place. For a broader look at all available weight-loss treatments, our treatment overview is a useful starting point.
When you are ready to have the dose conversation properly, speak to our prescribers through a free consultation, no waiting list, reviewed the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.